

Citations

1. Jacobson EL, Jacobson MK. Tissue NAD as a biochemical measure of niacin status in humans. *Methods Enzymol* 1997;280:221-230.
2. Welsh AL, Ede M. Inositol hexanicotinate for improved nicotinic acid therapy: preliminary report. *Int Rec Med* 1961;174:9-15.
3. Ziliotto GR, Lamberti G, Wagner A et al. [Comparative studies of the response of normolipemic and dyslipemic aged subjects to 2 forms of delayed-action nicotinic acid polyesters, pentaerythrol tetranicotinate and inositol hexanicotinate: results of a controlled crossover trial]. *Arch Sci Med (Torino)* 1977;134:359-394.
4. Head KA. Inositol hexaniacinate: a safer alternative to niacin. *Alt Med Rev* 1996;1:176-184.
5. Mosca L, Appel LJ, Benjamin EJ et al. Evidence-based guidelines for cardiovascular disease prevention in women. *Circulation* 2004;109:672-693.
6. Food and Nutrition Board, Institute of Medicine. Niacin. Dietary Reference Intakes: Thiamin, Riboflavin, Niacin, Vitamin B6, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington, DC: National Academy Press; 1998:123-149.
7. Fu CS, Swendseid ME, Jacob RA, McKee RW. Biochemical markers for assessment of niacin status in young men: levels of erythrocyte niacin coenzymes and plasma tryptophan. *J Nutr* 1989;119:1949-1955.
8. Hoffer A. Safety, side effects and relative lack of toxicity of nicotinic acid and nicotinamide. *Schizophrenia* 1969;1:78-87.
9. Winter SL, Boyer JL. Hepatic toxicity from large doses of vitamin B3 (nicotinamide). *N Engl J Med* 1973;289:1180-1182.
10. Pozzilli P, Visalli N, Signore A et al. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). *Diabetologia* 1995;38:848-852.
11. Knip M, Douek IF, Moore WP et al. Safety of high-dose nicotinamide: a review. *Diabetologia* 2000;43:1337-1345.
12. Garg R, Malinow M, Pettinger M et al. Niacin treatment increases plasma homocyst(e)ine levels. *Am Heart J* 1999;138:1082-1087.
13. Elam MB, Hunninghake DB, Davis KB et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. *Arterial Disease Multiple Intervention Trial. JAMA* 2000;284:1263-1270.
14. Grundy SM, Mok HY, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. *J Lipid Res* 1981;22:24-36.
15. Ding RW, Kolbe K, Merz B et al. Pharmacokinetics of nicotinic acid-salicylic acid interaction. *Clin Pharmacol Ther* 1989;46:642-647.
16. Whelan AM, Price SO, Fowler SF, Hainer BL. The effect of aspirin on niacin-induced cutaneous reactions. *J Fam Pract* 1992;34:165-168.
17. Jungnickel PW, Maloley PA, Vander Tuin EL et al. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. *J Gen Intern Med* 1997;12:591-596.
18. Bourgeois BF, Dodson WE, Ferrendelli JA. Interactions between primidone, carbamazepine, and nicotinamide. *Neurology* 1982;32:1122-1126.
19. Kryzhanovskii GN, Shandra AA. [Effect of diazepam, carbamazepine, sodium valproate and their combinations with vitamin preparations on epileptic activity]. *Biull Eksp Biol Med* 1985;100:545-547.
20. Cashin-Hemphill L, Spencer CA, Nicoloff JT et al. Alterations in serum thyroid hormonal indices with colestipol-niacin therapy. *Ann Intern Med* 1987;107:324-329.
21. Nessim SA, Chin HP, Alaupovic P, Blankenhorn DH. Combined therapy of niacin, colestipol, and fat-controlled diet in men with coronary bypass: effect on blood lipids and apolipoproteins. *Arteriosclerosis* 1983;3:568-573.
22. Blankenhorn DH, Azen SP, Nessim SA. Treatment of hyperlipidaemia and progression of atherosclerosis. *Lancet* 1983;2:1193.
23. Blankenhorn DH, Johnson RL, Nessim SA et al. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. *Control Clin Trials* 1987;8:356-387.
24. Blankenhorn DH, Nessim SA, Johnson RL et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. *JAMA* 1987;257:3233-3240.
25. Cashin-Hemphill L, Mack WJ, Pogoda JM et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. *JAMA* 1990;264:3013-3017.
26. Blankenhorn DH, Azen SP, Crawford DW et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. *Circulation* 1991;83:438-447.
27. Blankenhorn DH, Selzer RH, Mack WJ et al. Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures: a comparison of different measures of treatment effect. *Circulation* 1992;86:1701-1709.
28. Blankenhorn DH, Selzer RH, Crawford DW et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery: two- and four-year reduction of intima-media thickness measured by ultrasound. *Circulation* 1993;88:20-28.
29. Blankenhorn DH, Hodis HN. Atherosclerosis: reversal with therapy. *West J Med* 1993;159:172-179.

Citations and Reference Literature: Vitamin B3

30. Mack WJ, Selzer RH, Hodis HN et al. One-year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy. *Stroke* 1993;24:1779-1783.
31. Azen SP, Mack WJ, Cashin-Hemphill L et al. Progression of coronary artery disease predicts clinical coronary events: long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. *Circulation* 1996;93:34-41.
32. Blankenhorn DH, Alaupovic P, Wickham E et al. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors. *Circulation* 1990;81:470-476.
33. Azen SP, Cashin-Hemphill L, Pogoda J et al. Evaluation of human panelists in assessing coronary atherosclerosis. *Arterioscler Thromb* 1991;11:385-394.
34. Mack WJ, Selzer RH, Pogoda JM et al. Comparison of computer- and human-derived coronary angiographic end-point measures for controlled therapy trials. *Arterioscler Thromb* 1992;12:348-356.
35. Sprecher DL. Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review. *Am J Cardiol* 2000;86:46L-50L.
36. Ascaso JF, Fernandez-Cruz A, Gonzalez Santos P et al. Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum. *Am J Cardiovasc Drugs* 2004;4:299-314.
37. Spencer GA, Wirebaugh S, Whitney EJ. Effect of a combination of gemfibrozil and niacin on lipid levels. *J Clin Pharmacol* 1996;36:696-700.
38. Andrews TC, Whitney EJ, Green G et al. Effect of gemfibrozil± niacin± cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl. *Am J Cardiol* 1997;80:831-835.
39. Zema MJ. Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. *J Am Coll Cardiol* 2000;35:640-646.
40. Sakai T, Kamanna VS, Kashyap ML. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. *Arterioscler Thromb Vasc Biol* 2001;21:1783-1789.
41. Whitney EJ, Krasuski RA, Personius BE et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. *Ann Intern Med* 2005;142:95-104.
42. Dierkes J, Westphal S, Luley C. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. *Expert Opin Drug Saf* 2004;3:101-111.
43. Wald DS, Wald NJ, Morris JK, Law M. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. *BMJ* 2006;333:1114-1117.
44. Bruno-Joyce J, Dugas JM, MacCausland OE. Cerivastatin and gemfibrozil-associated rhabdomyolysis. *Ann Pharmacother* 2001;35:1016-1019.
45. Shek A, Ferrill MJ. Statin-fibrate combination therapy. *Ann Pharmacother* 2001;35:908-917.
46. Sacks FM. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. *Am J Cardiol* 2002;90:139-143.
47. Boden WE. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. *Curr Opin Cardiol* 2003;18:278-285.
48. Kashyap ML, Tavintharan S, Kamanna VS. Optimal therapy of low levels of high density lipoprotein-cholesterol. *Am J Cardiovasc Drugs* 2003;3:53-65.
49. Morgan JM, Carey CM, Lincoff A, Capuzzi DM. The effects of niacin on lipoprotein subclass distribution. *Prev Cardiol* 2004;7:182-187; quiz 188.
50. Morgan J, Carey C, Lincoff A, Capuzzi D. High-density lipoprotein subfractions and risk of coronary artery disease. *Curr Atheroscler Rep* 2004;6:359-365.
51. Studer M, Briel M, Leimenstoll B et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. *Arch Intern Med* 2005;165:725-730.
52. Wright RS, Bybee K, Miller WL et al. Reduced risks of death and CHF are associated with statin therapy administered acutely within the first 24 h of AMI. *Int J Cardiol* 2006;108:314-319.
53. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). *Diabetes Care* 2006;29:1478-1485.
54. Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. *Pharmacogenet Genomics* 2005;15:415-421.
55. Bilheimer DW. Long-term clinical tolerance of lovastatin and simvastatin. *Cardiology* 1990;77 Suppl 4:58-65.

Citations and Reference Literature: Vitamin B3

56. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med* 2005;352:1425-1435.
57. Go AS, Lee WY, Yang J et al. Statin therapy and risks for death and hospitalization in chronic heart failure. *JAMA* 2006;296:2105-2111.
58. Basu TK, Mann S. Vitamin B-6 normalizes the altered sulfur amino acid status of rats fed diets containing pharmacological levels of niacin without reducing niacin's hypolipidemic effects. *J Nutr* 1997;127:117-121.
59. Stead LM, Au KP, Jacobs RL et al. Methylation demand and homocysteine metabolism: effects of dietary provision of creatine and guanidinoacetate. *Am J Physiol Endocrinol Metab* 2001;281:E1095-E1100.
60. Basu TK, Makhani N, Sedgwick G. Niacin (nicotinic acid) in non-physiological doses causes hyperhomocysteinaemia in Sprague-Dawley rats. *Br J Nutr* 2002;87:115-119.
61. Malloy MJ, Kane JP, Kunitake ST, Tun P. Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. *Ann Intern Med* 1987;107:616-623.
62. Davignon J, Roederer G, Montigny M et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. *Am J Cardiol* 1994;73:339-345.
63. Jacobson TA, Jokubaitis LA, Amorosa LF. Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy. *Am J Med* 1994;96:64S-68S.
64. O'Keefe JH Jr, Harris WS, Nelson J, Windsor SL. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. *Am J Cardiol* 1995;76:480-484.
65. Jokubaitis LA. Fluvastatin in combination with other lipid-lowering agents. *Br J Clin Pract Suppl* 1996;77A:28-32.
66. Gardner SF, Marx MA, White LM et al. Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control. *Ann Pharmacother* 1997;31:677-682.
67. Guyton JR, Goldberg AC, Kreisberg RA et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. *Am J Cardiol* 1998;82:737-743.
68. Goldberg AC. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. *Am J Cardiol* 1998;82:35U-38U; discussion 39U-41U.
69. Goldberg A, Alagona P Jr, Capuzzi DM et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. *Am J Cardiol* 2000;85:1100-1105.
70. McKenney JM, McCormick LS, Schaefer EJ et al. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. *Am J Cardiol* 2001;88:270-274.
71. Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. *N Engl J Med* 2001;345:1583-1592.
72. Brown BG, Cheung MC, Lee AC et al. Antioxidant vitamins and lipid therapy: end of a long romance? *Arterioscler Thromb Vasc Biol* 2002;22:1535-1546.
73. Kashyap ML, McGovern ME, Berra K et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. *Am J Cardiol* 2002;89:672-678.
74. Wink J, Giacoppe G, King J. Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy. *Am Heart J* 2002;143:514-518.
75. Taylor AJ, Kent SM, Flaherty PJ et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. *Circulation* 2002;106:2055-2060.
76. Taylor AJ, Sullenberger LE, Lee HJ et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. *Circulation* 2004;110:3512-3517.
77. Taylor AJ, Sullenberger LE, Lee HJ. Atherosclerosis regression during open-label extended-release niacin following ARBITER 2. *American Heart Association Scientific Sessions* 2005. Dallas, Texas; 2005.
78. Stanek EJ, Sarawate C, Cziraky MJ, Charland SL. Impact of combined optimal lipid value achievement on risk of cardiovascular events in prevention, gender, and diabetes subgroups. *American Heart Association Scientific Sessions* 2005. Dallas, Texas; 2005.
79. Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. *Ann Intern Med* 1988;109:597-598.
80. Norman DJ, Illingworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. *N Engl J Med* 1988;318:46-47.
81. Langsjoen PH. Personal communication; 2005.
82. Stockley IH. *Drug Interactions*. 6th ed. London: Pharmaceutical Press; 2002.

Citations and Reference Literature: Vitamin B3

83. Fuccella LM, Goldaniga G, Lovisolo P et al. Inhibition of lipolysis by nicotinic acid and by acipimox. *Clin Pharmacol Ther* 1980;28:790-795.
84. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. *Lancet* 1963;1:785-789.
85. Heller B, Wang ZQ, Wagner EF et al. Inactivation of the poly(ADP-ribose) polymerase gene affects oxygen radical and nitric oxide toxicity in islet cells. *J Biol Chem* 1995;270:11176-11180.
86. Vague P, Vialettes B, Lassmann-Vague V, Vallo JJ. Nicotinamide may extend remission phase in insulin-dependent diabetes. *Lancet* 1987;1:619-620.
87. Pozzilli P, Visalli N, Ghirlanda G et al. Nicotinamide therapy in patients with newly-diagnosed type 1 (insulin-dependent) diabetes. *Diabetologia* 1988;31:533A.
88. Pozzilli P, Visalli N, Ghirlanda G et al. Nicotinamide increases C-peptide secretion in patients with recent onset type 1 diabetes. *Diabet Med* 1989;6:568-572.
89. Chase HP, Butler-Simon N, Garg S et al. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus. *Diabetologia* 1990;33:444-446.
90. Pozzilli P. The IMDIAB I multicentre study in newly diagnosed insulin dependent diabetic patients: final results. *Diabetologia* 1991;34:A29.
91. Paskova M, I. Ikao I, Trozova D, et al. Nicotinamide treatment in children with newly diagnosed type 1 diabetes mellitus. *Diabetologia* 1992;35:A203.
92. Elliott RB, Chase HP. Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. *Diabetologia* 1991;34:362-365.
93. Paul TL, Hramiak IM, Mahon JL et al. Nicotinamide and insulin sensitivity. *Diabetologia* 1993;36:369.
94. Herskowitz RD, Jackson RA, Soeldner JS, Eisenbarth GS. Pilot trial to prevent type I diabetes: progression to overt IDDM despite oral nicotinamide. *J Autoimmun* 1989;2:733-737.
95. Lampeter EF, Klinghammer A, Scherbaum WA et al. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. *Diabetes* 1998;47:980-984.
- 95a. Greenbaum CJ, Kahn SE, Palmer JP. Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM. *Diabetes* 1996;45(11):1631-1634.
96. Bingley PJ, Caldas G, Bonfanti R, Gale EA. Nicotinamide and insulin secretion in normal subjects. *Diabetologia* 1993;36:675-677.
97. Polo V, Saibene A, Pontiroli AE. Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas. *Acta Diabetol* 1998;35:61-64.
98. Berge KG. Side effects of nicotinic acid in treatment of hypercholesterolemia. *Geriatrics* 1961;16:416-422.
99. Christensen NA, Achor RW, Berge KG, Mason HL. Nicotinic acid treatment of hypercholesteremia: comparison of plain and sustained-action preparations and report of two cases of jaundice. *JAMA* 1961;177:546-550.
100. Lange K, Mahl M. A long-term study of the effect of nicotinic acid medication on hypercholesteremia. *Am J Med Sci* 1963;246:673-677.
101. Carlson LA, Havel RJ, Ekelund LG, Holmgren A. Effect of nicotinic acid on the turnover rate and oxidation of the free fatty acids of plasma in man during exercise. *Metabolism* 1963;12:837-845.
102. Molnar GD, Berge KG, Rosevear JW et al. The effect of nicotinic acid in diabetes mellitus. *Metabolism* 1964;13:181-190.
103. Miettinen TA, Taskinen MR, Pelkonen R, Nikkila EA. Glucose tolerance and plasma insulin in man during acute and chronic administration of nicotinic acid. *Acta Med Scand* 1969;186:247-253.
104. Gaut ZN, Solomon HM, Miller ON. Influence of antilipemic doses of nicotinic acid on carbohydrate tolerance and plasma insulin levels in man. *Diabetes* 1970;19:385.
105. Gaut ZN, Pocelinko R, Solomon HM, Thomas GB. Oral glucose tolerance, plasma insulin, and uric acid excretion in man during chronic administration of nicotinic acid. *Metabolism* 1971;20:1031-1035.
106. Carlson LA, Oro L. Effect of treatment with nicotinic acid for one month on serum lipids in patients with different types of hyperlipidemia. *Atherosclerosis* 1973;18:1-9.
107. Luria MH. Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio. *Arch Intern Med* 1988;148:2493-2495.
108. Kahn SE, Beard JC, Schwartz MW et al. Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. *Diabetes* 1989;38:562-568.
109. Henkin Y, Oberman A, Hurst DC, Segrest JP. Niacin revisited: clinical observations on an important but underutilized drug. *Am J Med* 1991;91:239-246.

Citations and Reference Literature: Vitamin B3

110. Gray DR, Morgan T, Chretien SD, Kashyap ML. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. *Ann Intern Med* 1994;121:252-258.
111. Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. *Arch Intern Med* 1994;154:73-82.
112. Illingworth DR, Stein EA, Mitchel YB et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial. *Arch Intern Med* 1994;154:1586-1595.
113. Guyton JR, Blazing MA, Hagar J et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. *Arch Intern Med* 2000;160:1177-1184.
114. Hannan F, Davoren P. Use of nicotinic acid in the management of recurrent hypoglycemic episodes in diabetes. *Diabetes Care* 2001;24:1301.
- 114a. Elam M, Hunninghake DB, Davis KB, et al. Effects of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. *JAMA* 2000;284:1263-1270.
115. Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. *Arch Intern Med* 2002;162:1568-1576.
116. Ishii N, Nishihara Y. Pellagra encephalopathy among tuberculous patients: its relation to isoniazid therapy. *J Neurol Neurosurg Psychiatry* 1985;48:628-634.
117. Shibata K, Marugami M, Kondo T. In vivo inhibition of kynurenine aminotransferase activity by isonicotinic acid hydrazide in rats. *Biosci Biotechnol Biochem* 1996;60:874-876.
118. Bender DA, Russell-Jones R. Isoniazid-induced pellagra despite vitamin-B6 supplementation. *Lancet* 1979;2:1125-1126.
119. Darvay A, Basarab T, McGregor JM, Russell-Jones R. Isoniazid induced pellagra despite pyridoxine supplementation. *Clin Exp Dermatol* 1999;24:167-169.
120. DiLorenzo PA. Pellagra-like syndrome associated with isoniazid therapy. *Acta Derm Venereol* 1967;47:318-322.
121. Stadler R, Orfanos CE, Immel C. [Drug-induced pellagra]. *Hautarzt* 1982;33:276-280.
122. Bjornstad RT. [Pellagra during isoniazid therapy]. *Tidsskr Nor Laegeforen* 1972;92:640-641.
123. Harrington CI. A case of pellagra induced by isoniazid therapy. *Practitioner* 1977;218:716-717.
124. Comaish JS, Felix RH, McGrath H. Topically applied niacinamide in isoniazid-induced pellagra. *Arch Dermatol* 1976;112:70-72.
125. Jarrett P, Duffill M, Oakley A, Smith A. Pellagra, azathioprine and inflammatory bowel disease. *Clin Exp Dermatol* 1997;22:44-45.
126. Gorbach SL, Bengt E. Gustafsson Memorial Lecture: Function of the normal human microflora. *Scand J Infect Dis Suppl* 1986;49:17-30.
127. De Simone C, Vesely R, Bianchi SB et al. The role of probiotics in modulation of the immune system in man and in animals. *Int J Immunother* 1993;9:23-28.
128. Conly JM, Stein K, Worobetz L, Rutledge-Harding S. The contribution of vitamin K2 (menaquinones) produced by the intestinal microflora to human nutritional requirements for vitamin K. *Am J Gastroenterol* 1994;89:915-923.
129. Conly J, Stein K. Reduction of vitamin K2 concentrations in human liver associated with the use of broad-spectrum antimicrobials. *Clin Invest Med* 1994;17:531-539.
130. Cummings JH, Macfarlane GT. Role of intestinal bacteria in nutrient metabolism. *JPEN J Parenter Enteral Nutr* 1997;21:357-365.
131. Hill MJ. Intestinal flora and endogenous vitamin synthesis. *Eur J Cancer Prev* 1997;6 Suppl 1:S43-S45.
132. Cunningham-Rundles S, Ahrne S, Bengmark S et al. Probiotics and immune response. *Am J Gastroenterol* 2000;95:S22-S25.
133. Macfarlane GT, Cummings JH. Probiotics, infection and immunity. *Curr Opin Infect Dis* 2002;15:501-506.
134. Gill HS. Probiotics to enhance anti-infective defences in the gastrointestinal tract. *Best Pract Res Clin Gastroenterol* 2003;17:755-773.
135. Reid G, Sanders ME, Gaskins HR et al. New scientific paradigms for probiotics and prebiotics. *J Clin Gastroenterol* 2003;37:105-118.
136. Khumalo NP, Murrell DF, Wojnarowska F, Kirtschig G. A systematic review of treatments for bullous pemphigoid. *Arch Dermatol* 2002;138:385-389.
137. Omray A, Varma KC. Evaluation of pharmacokinetic parameters of tetracycline hydrochloride upon oral administration with vitamin C and vitamin B complex. *Hindustan Antibiot Bull* 1981;23:33-37.
138. Peoples D, Fivenson DP. Linear IgA bullous dermatosis: successful treatment with tetracycline and nicotinamide. *J Am Acad Dermatol* 1992;26:498-499.

Citations and Reference Literature: Vitamin B3

139. Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. *J Am Acad Dermatol* 1993;28:998-1000.
140. Zemtsov A, Neldner KH. Successful treatment of dermatitis herpetiformis with tetracycline and nicotinamide in a patient unable to tolerate dapsone. *J Am Acad Dermatol* 1993;28:505-506.
141. Sawai T, Kitazawa K, Danno K et al. Pemphigus vegetans with oesophageal involvement: successful treatment with minocycline and nicotinamide. *Br J Dermatol* 1995;132:668-670.
142. Kawahara Y, Hashimoto T, Ohata K, Nishikawa T. Eleven cases of bullous pemphigoid treated with combination of minocycline and nicotinamide. *Eur J Dermatol* 1996;6:427-429.
143. Reiche L, Wojnarowska F, Mallon E. Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy. *Clin Exp Dermatol* 1998;23:254-257.
144. Yomada M, Komai A, Hashimoto T. Sublamina densa-type linear IgA bullous dermatosis successfully treated with oral tetracycline and niacinamide. *Br J Dermatol* 1999;141:608-609.
145. Shah SA, Ormerod AD. Dermatitis herpetiformis effectively treated with heparin, tetracycline and nicotinamide. *Clin Exp Dermatol* 2000;25:204-205.
146. Khanna N, Pandhi RK, Gupta S, Singh MK. Response of chronic bullous dermatosis of childhood to a combination of dapsone and nicotinamide. *J Eur Acad Dermatol Venereol* 2001;15:368.
147. Loo WJ, Dean D, Wojnarowska F. A severe persistent case of recurrent pemphigoid gestation is successfully treated with minocycline and nicotinamide. *Clin Exp Dermatol* 2001;26:726-727.
148. Chaidemenos GC. Tetracycline and niacinamide in the treatment of blistering skin diseases. *Clin Dermatol* 2001;19:781-785.
149. Hoffer A. Megavitamin B-3 therapy for schizophrenia. *Can Psychiatr Assoc J* 1971;16:499-504.
150. Mohler H, Polc P, Cumin R et al. Nicotinamide is a brain constituent with benzodiazepine-like actions. *Nature* 1979;278:563-565.
151. Ananth JV, Saxena BM, Lehmann HE, Ban TA. Combined administration of thioridazine and nicotinic acid in the treatment of geriatric patients. *Curr Ther Res Clin Exp* 1971;13:158-161.
152. Boiullat JE, Saxena BM, Lehmann HE, Ban TA. Combined administration of thioridazine, nicotinic acid, and fluoxymesterone in the treatment of geriatric patients. *Curr Ther Res Clin Exp* 1971;13:541-544.
153. Lehmann HE, Ban TA, Saxena BM. Nicotinic acid, thioridazine, fluoxymesterone and their combinations in hospitalized geriatric patients: a systematic clinical study. *Can Psychiatr Assoc J* 1972;17:315-320.
154. Chouinard G, Young SN, Annable L, Sourkes TL. Tryptophan-nicotinamide, imipramine and their combination in depression: a controlled study. *Acta Psychiatr Scand* 1979;59:395-414.
155. Shaw DM, MacSweeney DA, Hewland R, Johnson AL. Tricyclic antidepressants and tryptophan in unipolar depression. *Psychol Med* 1975;5:276-278.
156. Walinder J, Skott A, Carlsson A et al. Potentiation of the antidepressant action of clomipramine by tryptophan. *Arch Gen Psychiatry* 1976;33:1384-1389.
157. Walinder J, Carlsson A, Persson R. 5-HT reuptake inhibitors plus tryptophan in endogenous depression. *Acta Psychiatr Scand Suppl* 1981;290:179-190.
158. Actigall: Ciba, US; 1988.
159. Chenix: Reid-Rowell, US; 1988.
160. Agote M, Viaggi M, Kreimann E et al. Influence of nicotinamide on the radiosensitivity of normal and goitrous thyroid in the rat. *Thyroid* 2001;11:1003-1007.
161. Denekamp J, Fowler JF. ARCON—current status: summary of a workshop on preclinical and clinical studies. *Acta Oncol* 1997;36:517-525.
162. Hawkins DR, Bortin AW, Runyon RP. Orthomolecular psychiatry: niacin and megavitamin therapy. *Psychosomatics* 1970;11:517-521.
163. Pauling L, Wyatt RJ, Klein DF, Lipton MA. On the orthomolecular environment of the mind: orthomolecular theory. *Am J Psychiatry* 1974;131:1251-1267.
164. Parkhomets PK, Kuchmerovskaia TM, Donchenko GV et al. [Role of nicotinic acid and its derivatives in disorders of nervous system function]. *Ukr Biokhim Zh* 1995;67:3-11.
165. Hoffer A. The vitamin paradigm wars. *Townsend Lett Doctors Patients* 1996:56-60.
166. Green RG. Subclinical pellagra: its diagnosis and treatment. *Schizophrenia* 1970;2:70-79.
167. Osmond H, Hoffer A. Massive niacin treatment in schizophrenia: review of a nine-year study. *Lancet* 1962;1:316-319.
168. Wittenborn JR, Weber ES, Brown M. Niacin in the long-term treatment of schizophrenia. *Arch Gen Psychiatry* 1973;28:308-315.
169. Hoffer A. Vitamin B-3 dependent child. *Schizophrenia* 1971;3.

Citations and Reference Literature: Vitamin B3

170. Autry JH 3rd. Workshop on orthomolecular treatment of schizophrenia: a report. *Schizophr Bull* 1975;94-103.
171. Petrie WM, Ban TA. Vitamins in psychiatry: do they have a role? *Drugs* 1985;30:58-65.
172. Kramer MS, DiJohnson C, Davis P et al. L-Tryptophan in neuroleptic-induced akathisia. *Biol Psychiatry* 1990;27:671-672.
173. Bender DA, Smith WR. Inhibition of kynurenine hydrolase by benserazide, carbidopa and other aromatic hydrazine derivatives: evidence for sub-clinical iatrogenic niacin deficiency [proceedings]. *Biochem Soc Trans* 1978;6:120-122.
174. Bender DA, Earl CJ, Lees AJ. Niacin depletion in parkinsonian patients treated with l-dopa, benserazide and carbidopa. *Clin Sci (Lond)* 1979;56:89-93.
175. Stevens HP, Ostlere LS, Begent RH et al. Pellagra secondary to 5-fluorouracil. *Br J Dermatol* 1993;128:578-580.
176. Chen JS, Jan YY, Lin YC et al. Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas. *Anticancer Drugs* 1998;9:393-397.
177. Pasmans SG, Preesman AH, van Vloten WA. [Pellagra (deficiency of vitamin B3 or of the amino acid tryptophan): a disease still extant in The Netherlands]. *Ned Tijdschr Geneesk* 1998;142:1880-1882.
178. Hegyi J, Schwartz RA, Hegyi V. Pellagra: dermatitis, dementia, and diarrhea. *Int J Dermatol* 2004;43:1-5.
179. Rasool AA, Hussain AA, Dittert LW. Solubility enhancement of some water-insoluble drugs in the presence of nicotinamide and related compounds. *J Pharm Sci* 1991;80:387-393.
180. Gurakar A, Hoeg JM, Kostner G et al. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. *Atherosclerosis* 1985;57:293-301.
181. Turenne SD, Seeman M, Ross BM. An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response. *Schizophr Res* 2001;50:191-197.
182. Clarkes R. Niacin for nicotine? *Lancet* 1980;1:936.
183. Rockwell KA Jr. Potential interaction between niacin and transdermal nicotine. *Ann Pharmacother* 1993;27:1283-1288.
184. Sudan BJ. Comment: niacin, nicotine, and flushing. *Ann Pharmacother* 1994;28:1113.
185. Rose DP, Adams PW. Oral contraceptives and tryptophan metabolism: effects of oestrogen in low dose combined with a progestagen and of a low-dose progestagen (megestrol acetate) given alone. *J Clin Pathol* 1972;25:252-258.
186. Brown RR, Rose DP, Leklem JE, Linkswiler HM. Effects of oral contraceptives on tryptophan metabolism and vitamin B6 requirements in women. *Acta Vitaminol Enzymol* 1975;29:151-157.
187. Briggs M. Oral contraceptives and vitamin requirements [letter]. *Med J Aust* 1975;1:407.
188. Leklem JE, Brown RR, Rose DP et al. Metabolism of tryptophan and niacin in oral contraceptive users receiving controlled intakes of vitamin B6. *Am J Clin Nutr* 1975;28:146-156.
189. Driskell JA, Geders JM, Urban MC. Vitamin B6 status of young men, women, and women using oral contraceptives. *J Lab Clin Med* 1976;87:813-821.
190. Thorp VJ. Effect of oral contraceptive agents on vitamin and mineral requirements. *J Am Diet Assoc* 1980;76:581-584.
191. Webb JL. Nutritional effects of oral contraceptive use: a review. *J Reprod Med* 1980;25:150-156.
192. Veninga KS. Effects of oral contraceptives on vitamins B6, B12, C, and folacin. *J Nurse Midwifery* 1984;29:386-390.
193. Tyrer LB. Nutrition and the pill. *J Reprod Med* 1984;29:547-550.
194. Cervantes-Laurean D, McElvaney NG, Moss J. Niacin. In: Shils M, Olson JA, Shike M, Ross AC, eds. *Nutrition in Health and Disease*. 9th ed. Baltimore: Williams & Wilkins; 1999:401-411.
195. Prasad AS, Oberleas D, Moghissi KS et al. Effect of oral contraceptive agents on nutrients. II. Vitamins. *Am J Clin Nutr* 1975;28:385-391.
196. Bamji MS, Safaya S, Prema K. Low-dose injectable contraceptive norethisterone enanthate 20mg monthly. II. Metabolic side effects. *Contraception* 1981;23:23-36.
197. Shibata K, Fukuwatari T, Sugimoto E. Effects of dietary pyrazinamide, an antituberculosis agent, on the metabolism of tryptophan to niacin and of tryptophan to serotonin in rats. *Biosci Biotechnol Biochem* 2001;65:1339-1346.
198. Dearing BD, Lavie CJ, Lohmann TP, Genton E. Niacin-induced clotting factor synthesis deficiency with coagulopathy. *Arch Intern Med* 1992;152:861-863.
199. Coppola A, Brady PG, Nord HJ. Niacin-induced hepatotoxicity: unusual presentations. *South Med J* 1994;87:30-32.
200. Philipp CS, Cisar LA, Saidi P, Kostis JB. Effect of niacin supplementation on fibrinogen levels in patients with peripheral vascular disease. *Am J Cardiol* 1998;82:697-699, A699.
201. Chesney CM, Elam MB, Herd JA et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). *Am Heart J* 2000;140:631-636.

Citations and Reference Literature: Vitamin B3

202. Odetti P, Cheli V, Carta G et al. Effect of nicotinic acid associated with retinol and tocopherols on plasma lipids in hyperlipoproteinaemic patients. *Pharmatherapeutica* 1984;4:21-24.
203. Hodis HN, Mack WJ, LaBree L et al. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. *JAMA* 1995;273:1849-1854.
204. Cheung MC, Wolfbauer G, Kennedy H et al. Plasma phospholipid transfer protein activity in patients with low HDL and cardiovascular disease treated with simvastatin and niacin. *Biochim Biophys Acta* 2001;1537:117-124.
205. Cheung MC, Zhao XQ, Chait A et al. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. *Arterioscler Thromb Vasc Biol* 2001;21:1320-1326.
206. Matthan NR, Giovanni A, Schaefer EJ et al. Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL. *J Lipid Res* 2003;44:800-806.
207. Vivekananthan DP, Penn MS, Sapp SK et al. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. *Lancet* 2003;361:2017-2023.
208. McCarty MF. Co-administration of equimolar doses of betaine may alleviate the hepatotoxic risk associated with niacin therapy. *Med Hypotheses* 2000;55:189-194.
209. Urberg M, Zemel MB. Evidence for synergism between chromium and nicotinic acid in the control of glucose tolerance in elderly humans. *Metabolism* 1987;36:896-899.
210. Lefavi RG, Anderson RA, Keith RE et al. Efficacy of chromium supplementation in athletes: emphasis on anabolism. *Int J Sport Nutr* 1992;2:111-122.
211. Hathcock JN. Vitamins and minerals: efficacy and safety. *Am J Clin Nutr* 1997;66:427-437.
212. Mertz W. Chromium research from a distance: from 1959 to 1980. *J Am Coll Nutr* 1998;17:544-547.
213. Bolkent S, Yanardag R, Doger MM. Beneficial effects of combined treatment with niacin and chromium on the liver of hyperlipemic rats. *Biol Trace Elem Res* 2004;101:219-229.
214. Keszthelyi Z, Past T, Lukats B et al. The central effect of chromium on glucose metabolism. *Pharmacopsychiatry* 2004;37:242.
215. Thomas VL, Gropper SS. Effect of chromium nicotinic acid supplementation on selected cardiovascular disease risk factors. *Biol Trace Elem Res* 1996;55:297-305.
216. Crawford V, Scheckenbach R, Preuss HG. Effects of niacin-bound chromium supplementation on body composition in overweight African-American women. *Diabetes Obes Metab* 1999;1:331-337.
217. Preuss HG, Bagchi D, Bagchi M. Protective effects of a novel niacin-bound chromium complex and a grape seed proanthocyanidin extract on advancing age and various aspects of syndrome X. *Ann NY Acad Sci* 2002;957:250-259.
218. Yeganeh B, Moshtaghi-Kashanian GR, Declercq V, Moghadasian MH. Combination of dietary phytosterols plus niacin or fenofibrate: effects on lipid profile and atherosclerosis in apo E-KO mice. *J Nutr Biochem* 2005;16:222-228.
219. Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. *Am Heart J* 2002;143:356-365.
220. Janikula M. Policosanol: a new treatment for cardiovascular disease? *Altern Med Rev* 2002;7:203-217.
221. Uribarri E, Laguna A, Sierra R, Ricardo Y. Physico-mechanical characterization of policosanol, a novel hypocholesterolemic drug. *Drug Dev Ind Pharm* 2002;28:89-93.
222. Cholesterol-lowering action of policosanol compares well to that of pravastatin and lovastatin. *Cardiovasc J S Afr* 2003;14:161.
223. Castano G, Mas R, Fernandez L et al. Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study. *Angiology* 2003;54:25-38.
224. Berthold HK, Unverdorben S, Degenhardt R et al. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. *JAMA* 2006;295:2262-2269.
225. Ban TA. On-going national collaborative studies in Canada: niacin in the treatment of schizophrenias. *Psychopharmacol Bull* 1969;5:5-20.
226. Ananth JV, Ban TA, Lehmann HE. Potentiation of therapeutic effects of nicotinic acid by pyridoxine in chronic schizophrenics. *Can Psychiatr Assoc J* 1973;18:377-383.
227. Petrie WM, Ban TA, Ananth JV. The use of nicotinic acid and pyridoxine in the treatment of schizophrenia. *Int Pharmacopsychiatry* 1981;16:245-250.
228. Vannucchi H, Kutnink MD, Sauberlich M, Howerde E. Interaction among niacin, vitamin B6 and zinc in rats receiving ethanol. *Int J Vitam Nutr Res* 1986;56:355-362.
229. Vannucchi H, Moreno FS. Interaction of niacin and zinc metabolism in patients with alcoholic pellagra. *Am J Clin Nutr* 1989;50:364-369.

Reference Literature

- [No authors listed.] Adult Treatment Panel III (ATP III) guidelines: NHLBI slide show. Available at: http://hin.nhlbi.nih.gov/ncep_slds/atp3iii/slide101.htm. Accessed June 14, 2002.
- [No authors listed.] Clofibrate and niacin in coronary heart disease. *JAMA* 1975;231(4):360-381.
- [No authors listed.] Drug evaluations subscription: vol. II, section 10. Chicago: American Medical Association; 1994.
- [No authors listed.] Drug facts and comparisons. St Louis: Facts and Comparisons, Inc; 1999.
- [No authors listed.] Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001;285(19):2486-2497.
- [No authors listed.] Lipid-lowering drugs. *Med Lett Drugs Ther* 1985;27(695):74-76.
- [No authors listed.] Product information: Actigall. Summit, NJ: Ciba; 1988.
- [No authors listed.] Product information: Baycol (TM), cerivastatin sodium. West Haven, CT: Bayer Corporation; 1997.
- [No authors listed.] Product information: Chenix. Marietta, GA: Reid-Rowell; 1988.
- [No authors listed.] Product information: Lipitor (TM), atorvastatin. Morris Plains, NJ: Parke-Davis; 1996.
- [No authors listed.] Product information: Niaspan(R), niacin, extended release tablet. Miami, FL: Kos Pharmaceuticals; 1997.
- [No authors listed.] Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). *JAMA* 1993;269(23):3015-3023.
- [No authors listed.] Vitamin B complex, Niacin. In: McEvoy GK, ed. American Hospital Formulary Service Drug Information. Bethesda, MD: American Society of Hospital Pharmacists; 1995:1685-1687.
- Alderman JD, Pasternak RC, Sacks FM, et al. Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. *Am J Cardiol* 1989;64(12):725-729.
- Ames BN. A role for supplements in optimizing health: the metabolic tune-up. *Arch Biochem Biophys* 2004;423(1):227-234. (Review)
- Ames BN. DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. *Mutat Res* 2001;475(1-2):7-20. (Review)
- Ames BN. Increasing longevity by tuning up metabolism: to maximize human health and lifespan, scientists must abandon outdated models of micronutrients. *EMBO Rep* 2005;6(Suppl 1):S20-24. (Review)
- Ames BN. Micronutrient deficiencies: a major cause of DNA damage. *Ann N Y Acad Sci* 1999;889:87-106. (Review)
- Ames BN. The metabolic tune-up: metabolic harmony and disease prevention. *J Nutr* 2003;133(5):1544S-1548S. (Review)
- Ames BN, Atamna H, Killilea DW. Mineral and vitamin deficiencies can accelerate the mitochondrial decay of aging. *Mol Aspects Med* 2005;26(4-5):363-378. (Review)
- Ames BN, Elson-Schwab I, Silver EA. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased K(m)): relevance to genetic disease and polymorphisms. *Am J Clin Nutr* 2002;75(4):616-658. (Review)
- Amiel SA, Caprio S, Sherwin RS, et al. Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. *J Clin Endocrinol Metab* 1991;72:277-282.
- Antoon AY, Donovan DK. Burn injuries. In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson textbook of pediatrics. Philadelphia: Saunders; 2000:287-294.
- Baggenstoss AH, Christensen NA, Berge KG, et al. Fine structural changes in the liver in hypercholesteremic patients receiving long-term nicotinic acid therapy. *Mayo Clin Proc* 1967;42(7):385-399.
- Ban TA. On-going national collaborative studies in Canada: niacin in the treatment of schizophrenias. *Psychopharmacol Bull* 1969;5(3):5-20. (Review)
- Bays HE, Dujovne CA. Drug interactions of lipid-altering drugs. *Drug Safety* 1998;19(5):355-371. (Review)
- Bechgaard H, Jespersen S. GI absorption of niacin in humans. *J Pharm Sci* 1977;66:871-872.
- Belalcázar LM, Ballantyne CM. Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol. *Prog Cardiovasc Dis* 1998;41:151-174. (Review)
- Berge KG, Canner PL. Coronary drug project: experience with niacin: Coronary Drug Project Research Group. *Eur J Clin Pharmacol* 1991;40(Suppl 1):S49-51.
- Berk MA, Lorincz AL. The treatment of bullous pemphigoid with tetracycline and niacinamide: a preliminary report. *Arch Dermatol* 1986;122:670-674.
- Berge KG. Side effects of nicotinic acid in treatment of hypercholesterolemia. *Geriatrics* 1961;16:416-422.
- Berge KG, Achor RW, Christensen NA, et al. Hypercholesteremia and nicotinic acid: a long term study. *Am J Med* 1961;31:24-36.

Citations and Reference Literature: Vitamin B3

- Berthold HK, Unverdorben S, Degenhardt R, et al. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. *JAMA* 2006;295:2262-2269.
- Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. *Hepatology* 2005;42(2):481-489.
- Boden WE. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. *Curr Opin Cardiol* 2003;18(4):278-285. (Review)
- Bohler A, Moll C, Schaffner A, et al. [Alcoholic pellagra encephalopathy: an underestimated treatable entity.] *Schweiz Med Wochenschr* 1994;124(17):720-724. [German]
- Boyonoski AC, Spronck JC, Gallacher LM, et al. Niacin deficiency decreases bone marrow poly(ADP-ribose) and the latency of ethylnitrosourea-induced carcinogenesis in rats. *J Nutr* 2002;132(1):108-114.
- Brody T. Nutritional biochemistry. 2nd ed. San Diego: Academic Press; 1999.
- Braham JE, Villareal A, Bressani R. Effect of lime treatment of corn on the availability of niacin for cats. *J Nutr* 1962;76:183-186.
- Bressani R, Gómez-Brenes R, Scrimshaw NS. Effect of processing on distribution and in vitro availability of niacin of corn (*Zea mays*). *Food Technol* 1961;15:450-454.
- Bressani R, Scrimshaw NS. Effect of lime treatment on in-vitro availability of essential amino acids and solubility of protein fractions in com. *J Agric Food Chem* 1958;6:774-778.
- Brown BG, Bardsley J, Poulin D, et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. *Am J Cardiol* 1997;80(2):111-115.
- Brown BG, Zambon A, Poulin D, et al. Use of niacin, statins, and resins in patients with combined hyperlipidemia. *Am J Cardiol* 1998;81(4A):52B-59B.
- Brown RR, Ozaki Y, Datta SP, et al. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. *Adv Exp Med Biol* 1991;294:425-435.
- Brown WV. Niacin for lipid disorders: indications, effectiveness, and safety. *Postgrad Med* 1995;98(2):185-9, 192-193.
- Brunzell DH, Russell DS, Picciotto MR. In vivo nicotine treatment regulates mesocorticolimbic CREB and ERK signaling in C57Bl/6J mice. *J Neurochem* 2003;84(6):1431-1441.
- Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. *Arterioscler Thromb Vasc Biol* 1999;19(2):187-195. (Review)
- Burkart V, Koike T, Brenner HH, et al. Oxygen radicals generated by the enzyme xanthine oxidase lyse rat pancreatic islet cells in vitro. *Diabetologia* 1992;35:1028-1034.
- Calabresi L, Villa B, Canavesi M, et al. An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. *Metabolism* 2004;53:153-158.
- Calabro P, Yeh ET. The pleiotropic effects of statins. *Curr Opin Cardiol* 2005;20(6):541-546.
- Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. *J Am Coll Cardiol* 1986;8(6):1245-1255.
- Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. *Am J Cardiol* 1998;82:74U-81U.
- Capuzzi DM, Morgan JM, Weiss RJ, et al. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. *Am J Cardiol* 2003;91:1304-1310.
- Carlson LA, Havel RJ, Ekelund LG, et al. Effect of nicotinic acid on the turnover rate and oxydation of the free fatty acids of plasma in man during exercise. *Metabolism* 1963;12(9):837-845.
- Carlson LA, Oro L. Effect of treatment of nicotinic acid for one month on serum lipids in patients with different types of hyperlipidemia. *Atherosclerosis* 1973;18(1):1-9.
- Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. *Acta Med Scand* 1988;223(5):405-418.
- Castiello RJ, Lynch PJ. Pellagra and the carcinoid syndrome. *Arch Dermatol* 1972;105(4):574-577.
- Cervantes-Laurean D, McElvaney NG, Moss J. Niacin. In: Shils M, Olson JA, Shike M, et al, eds. *Nutrition in health and disease*. 9th ed. Baltimore: Williams & Wilkins; 1999:401-411.
- Chan DC, Watts GF, Barrett PH, et al. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. *Diabetes* 2002;51(8):2377-2386.
- Chase HP, Butler-Simon N, Garg S, et al. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin dependent) diabetes mellitus. *Diabetologia* 1990;33:444-446.
- Cho S, Choi JC, Choi JH, et al. Wet pellagra. *Int J Dermatol* 2001;40(8):543-544.

Citations and Reference Literature: Vitamin B3

- Christensen NA, Achor RW, Berge KG, et al. Nicotinic acid treatment of hypercholesterolemia, comparison of plain and sustained action preparations and report of two cases of jaundice. *JAMA* 1961;177:546-550.
- Cohen JC, Boerwinkle E, Mosley TH Jr, et al. Sequence variations in PCSK9, low LDL, and protection against coronary artery disease. *N Engl J Med* 2006;354:1264-1272.
- Cohen L, Morgan J. Effectiveness of individualized long-term therapy with niacin and probucol in reduction of serum cholesterol. *J Fam Pract* 1988;26:145-150.
- Cravioto RO, Massieu GH, Cravioto OY, et al. Effect of untreated corn and Mexican tortilla upon the growth of rats on a niacin-tryptophan deficient diet. *J Nutr* 1952;48:453-459.
- Crouse JR III. New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug. *Coron Artery Dis* 1996;7:321-326.
- Cumming RG, Mitchell P, Smith W. Diet and cataract: the Blue Mountains Eye Study. *Ophthalmology* 2000;107(3):450-456.
- Cunningham JJ. Micronutrients as nutraceutical interventions in diabetes mellitus. *J Am Coll Nutr* 1998;17:7-10.
- Cupo MA, Donaldson WE. Effects of lead and niacin on tryptophan and serotonin metabolism. *Drug Nutr Interact* 1988;5(4):297-308.
- Darras BT, Ampola MG, Dietz WH, et al. Intermittent dystonia in Hartnup disease. *Pediatr Neurol* 1989;5:118-120.
- De-Souza DA, Greene LJ. Pharmacological nutrition after burn injury. *J Nutr* 1998;128:797-803.
- Denekamp J, Fowler JF. ARCON: current status: summary of a workshop on preclinical and clinical studies. *Acta Oncol* 1997;36:517-525.
- Donner Von G, Fisher FW. [Zur Beeinflussung der Serumlipide und -lipoproteine durch den Hexanicotinsäureester des m-Inositol.] *Arzneimittelforschung* 1961;11:110-113.
- Doyle W, Crawford MA, Wynn AH, et al. The association between maternal diet and birth dimensions. *J Nutr Med* 1990;1:9-17.
- Dragan L, Eng AM, Lam S, et al. Tetracycline and niacinamide: treatment alternatives in ocular cicatricial pemphigoid. *Cutis* 1999;63:181-183.
- Elam M, Hunninghake DB, Davis KB, et al. Effects of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial: Arterial Disease Multiple Intervention Trial. *JAMA* 2000;284:1263-1270.
- Elliott RB, Chase HP. Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. *Diabetologia* 1991;34:362-365.
- Elliott RB, Pilcher CC, Fergusson DM, et al. A population based strategy to prevent insulin-dependent diabetes using nicotinamide. *J Pediatr Endocrinol Metab* 1996;9:501-509.
- Elliott RB, Pilcher CC, Stewart A, et al. The use of nicotinamide in the prevention of type 1 diabetes. *Ann N Y Acad Sci* 1993;696:333-341.
- Elvehjem CA, Madden RJ, Strong FM, et al. The isolation and identification of the anti-black tongue factor: 1937. *J Biol Chem* 2002;277(34):e22.
- Estep DL, Gay GR, Rappolt RT Sr. Preliminary report of the effects of propranolol HCl on the discomfort caused by niacin. *Clin Toxicol* 1977;11(3):325-328.
- Flodin N. Pharmacology of micronutrients. New York: Alan R. Liss, Inc; 1988.
- Food and Nutrition Board, Institute of Medicine. Niacin: dietary reference intakes: thiamin, riboflavin, niacin, vitamin B-6, vitamin B-12, pantothenic acid, biotin, and choline. Washington, DC: National Academy Press; 1998:123-149.
- Foody JM, Shah R, Galusha D, et al. Statins and mortality among elderly patients hospitalized with heart failure. *Circulation* 2006;113(8):1086-1092.
- Forsyth LM, Preuss HG, MacDowell AL, et al. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. *Ann Allergy Asthma Immunol* 1999;82:185-191.
- Franceschi S, Bidoli E, Negri E, et al. Role of macronutrients, vitamins and minerals in the aetiology of squamous-cell carcinoma of the oesophagus. *Int J Cancer* 2000;86(5):626-631.
- Freedman JE. Antioxidant versus lipid-altering therapy: some answers, more questions. *N Engl J Med* 2001;345(22):1636-1637.
- Fu CS, Swendseid ME, Jacob RA, et al. Biochemical markers for assessment of niacin status in young men: levels of erythrocyte niacin coenzymes and plasma tryptophan. *J Nutr* 1989;119(12):1949-1955.
- Fuccella LM, Goldaniga G, Lovisco P, et al. Inhibition of lipolysis by nicotinic acid and acipimox. *Clin Pharmacol Ther* 1980;28:790-795.
- Gaby AR. Natural treatments for osteoarthritis. *Altern Med Rev* 1999;4(5):330-341.
- Garg A. Lipid-lowering therapy and macrovascular disease in diabetes mellitus. *Diabetes* 1992;41(Suppl 2):111-115.
- Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. *JAMA* 1990;264:723-726.

Citations and Reference Literature: Vitamin B3

- Garg R, Malinow M, Pettinger M, et al. Niacin treatment increases plasma homocyst(e)ine levels. *Am Heart J* 1999;138:1082-1087.
- Gardner SF, Schneider EF, Granberry MC, et al. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. *Pharmacotherapy* 1996;16:419-423.
- Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. *Am J Health Syst Pharm* 1995;52(15):1639-1645. (Review)
- Gascard E, Cherif AA, Moulard JC. [Pellagra and pellagroud syndromes: 21 cases.] *Mars Med* 1969;106(9):695-697. (Case reports) [French]
- Gaut ZN, Pocelinko R, Solomon HM, et al. Oral glucose tolerance, plasma insulin, and uric acid excretion in man during chronic administration of nicotinic acid. *Metabolism* 1971;20(11):1031-1035.
- Gaut ZN, Solomon HM, Miller ON. Influence of antilipemic doses of nicotinic acid on carbohydrate tolerance and plasma insulin levels in man. *Diabetes* 1970;19:385.
- Gensler HL, Williams T, Huang AC, et al. Oral niacin prevents photocarcinogenesis and photoimmunosuppression in mice. *Nutr Cancer* 1999;34(1):36-41.
- Gibbons LW, Gonzalez V, Gordon N, et al. The prevalence of side effects with regular and sustained-release nicotinic acid. *Am J Med* 1995;99(4):378-385.
- Glen AI, Cooper SJ, Rybakowski J, et al. Membrane fatty acids, niacin flushing and clinical parameters. *Prostaglandins Leukot Essent Fatty Acids* 1996;55(1-2):9-15.
- Go AS, Iribarren C, Chandra M et al; Atherosclerotic Disease, Vascular Function and Genetic Epidemiology (ADVANCE) Study: statin and beta-blocker therapy and the initial presentation of coronary heart disease. *Ann Intern Med* 2006;144(4):229-238.
- Go AS, Lee WY, Yang J, et al. Statin therapy and risks for death and hospitalization in chronic heart failure. *JAMA* 2006;296 2105-2111.
- Goldberg AC. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. *Am J Cardiol* 1998;82(12A):35U-38U.
- Goldberg A, Alagona P Jr, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. *Am J Cardiol* 2000;85(9):1100-1105.
- Goldstein JA. Niacin and acute psychotic psychosis. *Biol Psychiatry* 1984;19(2):272-273.
- Golomb BA. Implications of statin adverse effects in the elderly. *Expert Opin Drug Safety* 2005;4(3):389-397.
- Golomb BA, Kane T, Dimsdale JE. Severe irritability associated with statin cholesterol-lowering drugs. *QJM* 2004;97(4):229-235.
- Gomez de la Torre R, Blanco Zorroza B, Claros Gonzalez IJ, et al. [Pellagra: manifestations of a disease...not forgotten?] *An Med Interna* 2000;17(8):450-451. [Spanish]
- Gray DR, Morgan T, Chretien SD, et al. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. *Ann Intern Med* 1994;121(4):252-258.
- Green AR, Bloomfield MR, Woods HF, et al. Metabolism of an oral tryptophan load by women and evidence against the induction of tryptophan pyrrolase by oral contraceptives. *Br J Clin Pharmacol* 1978;5(3):233-241.
- Green RF. Subclinical pellagra and idiopathic hypogeusia. *JAMA* 1971;218(8):1303.
- Green RG. Subclinical pellagra: its diagnosis and treatment. *Schizophrenia* 1970;2:70-79.
- Greenbaum CJ, Kahn SE, Palmer JP. Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM. *Diabetes* 1996;45(11):1631-1634.
- Gregory JF III. Nutritional properties and significance of vitamin glycosides. *Annu Rev Nutr* 1998;18:277-296.
- Grundy SM, Mok HY, Zech L, et al. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. *J Lipid Res* 1981;22(1):24-36.
- Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. *Arch Intern Med* 2002;162:1568-1576.
- Gugler R. Clinical pharmacokinetics of hypolipidaemic drugs. *Clin Pharmacokinet* 1978;3(6):425-439.
- Guyton JR. Effect of niacin on atherosclerotic cardiovascular disease. *Am J Cardiol* 1998;82:18U-23U, 39U-41U. (Review)
- Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs. gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol: Niaspan-Gemfibrozil Study Group. *Arch Intern Med* 2000;160(8):1177-1184.
- Guyton JR, Capuzzi DM. Treatment of hyperlipidemia with combined niacin-statin regimens. *Am J Cardiol* 1998;82(12A):82U-86U.
- Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. *Am J Cardiol* 1998;82:737-743.
- Hageman GJ, Stierum RH. Niacin, poly(ADP-ribose) polymerase-1 and genomic stability. *Mutat Res* 2001;475(1-2):45-56.

Citations and Reference Literature: Vitamin B3

- Hageman GJ, Stierum RH, van Herwijnen MH, et al. Nicotinic acid supplementation: effects on niacin status, cytogenetic damage, and poly(ADP-ribosylation) in lymphocytes of smokers. *Nutr Cancer* 1998;32(2):113-120.
- Handfield-Jones S, Jones S, Peachey R. High dose nicotinamide in the treatment of necrobiosis lipoidica. *Br J Dermatol* 1988;118:693-696.
- Hannan F, Davoren P. Use of nicotinic acid in the management of recurrent hypoglycemic episodes in diabetes. *Diabetes Care* 2001;24(7):1301.
- Hakozaki T, Minwalla L, Zhuang J, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. *Br J Dermatol* 2002;147:20-31.
- Hawkins DR, Bortin AW, Runyon RP. Orthomolecular psychiatry: niacin and megavitamin therapy. *Psychosomatics* 1970;11:517-521.
- Head A. Treatment of intermittent claudication with inositol nicotinate. *Practitioner* 1986;230:49-54.
- Head KA. Inositol hexaniacinate: a safer alternative to niacin. *Alt Med Rev* 1996;1(3):176-184. (Review)
- Hegyi J, Schwartz RA, Hegyi V. Pellagra: dermatitis, dementia, and diarrhea. *Int J Dermatol* 2004;43(1):1-5. (Review)
- Hendler SS, Rorvik DR, eds. *PDR for nutritional supplements*. Montvale, NJ: Medical Economics Company, Inc; 2001.
- Henkin Y, Oberman A, Hurst DC, et al. Niacin revisited: clinical observations on an important but underutilized drug. *Am J Med* 1991;91(3):239-246.
- Hermite L, Vialettes B, Atleff N, et al. High dose nicotinamide fails to prevent diabetes in BB rats. *Autoimmunity* 1989;5(1-2):79-86.
- Hoffer A. Megavitamin B-3 therapy for schizophrenia. *Can Psychiatr Assoc J* 1971;16:499-504.
- Hoffer A. Safety, side effects and relative lack of toxicity of nicotinic acid and nicotinamide. *Schizophrenia* 1969;1:78-87.
- Hoffer A. The vitamin paradigm wars. *Townsend Letters for Doctors and Patients* 1996;56-60.
- Hoffer A. Vitamin B-3 dependent child. *Schizophrenia* 1971;3:107-113.
- Holt GA. Food and drug interactions. Chicago: Precept Press; 1998:82-83. (Review)
- Horrobin DF. Schizophrenia: a biochemical disorder? *Biomedicine* 1980;32(2):54-55.
- Hudgins AP. Niacin for dysmenorrhea. *Am Pract Dig Treat* 1952;3(11):892-893.
- Hudgins AP. Vitamins P, C and niacin for dysmenorrhea therapy. *West J Surg Obstet Gynecol* 1954;62(12):610-611.
- Hyponen E. Micronutrients and the risk of type 1 diabetes: vitamin D, vitamin E, and nicotinamide. *Nutr Rev* 2004;62(9):340-347. (Review)
- Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial. *Arch Intern Med* 1994;154(14):1586-1595.
- Iribarren C, Belcher JD, Jacobs DR Jr, et al. Relationship of lipoproteins, apolipoproteins, triglycerides and lipid ratios to plasma total cholesterol in young adults: the CARDIA Study: Coronary Artery Risk Development in Young Adults. *J Cardiovasc Risk* 1996;3(4):391-396.
- Iribarren C, Folsom AR, Jacobs DR Jr, et al. Association of serum vitamin levels, LDL susceptibility to oxidation, and autoantibodies against MDA-LDL with carotid atherosclerosis: a case-control study. The ARIC Study Investigators: Atherosclerosis Risk in Communities. *Arterioscler Thromb Vasc Biol* 1997;17(6):1171-1177.
- Iribarren C, Jacobs DR, Sadler M, et al. Hemorrhagic stroke: is the association confined to elderly men? The Kaiser Permanente Medical Care Program. *Stroke* 1996;27(11):1993-1998.
- Iribarren C, Jacobs DR Jr, Sidney S, et al. Cohort study of serum total cholesterol and in-hospital incidence of infectious diseases. *Epidemiol Infect* 1998;121(2):335-347.
- Iribarren C, Jacobs DR Jr, Sidney S, et al. Serum total cholesterol and risk of hospitalization, and death from respiratory disease. *Int J Epidemiol* 1997;26(6):1191-1202.
- Iribarren C, Jacobs DR Jr, Slaterry ML, et al. Epidemiology of low total plasma cholesterol concentration among young adults: the CARDIA study: Coronary Artery Risk Development in Young Adults. *Prev Med* 1997;26(4):495-507.
- Iribarren C, Reed DM, Burchfiel CM, et al. Serum total cholesterol and mortality: confounding factors and risk modification in Japanese-American men. *JAMA* 1995;273(24):1926-1932.
- Iribarren C, Reed DM, Chen R, et al. Low serum cholesterol and mortality: which is the cause and which is the effect? *Circulation* 1995;92(9):2396-2403.
- Iribarren C, Reed DM, Wergowske G, et al. Serum cholesterol level and mortality due to suicide and trauma in the Honolulu Heart Program. *Arch Intern Med* 1995;155(7):695-700.
- Iribarren C, Sharp D, Burchfiel CM, et al. Association of serum total cholesterol with coronary disease and all-cause mortality: multivariate correction for bias due to measurement error. *Am J Epidemiol* 1996;143(5):463-471.
- Isaac S. The "gauntlet" of pellagra. *Int J Dermatol* 1998;37(8):599.

Citations and Reference Literature: Vitamin B3

- Jackson TM, Rawling JM, Roebuck BD, et al. Large supplements of nicotinic acid and nicotinamide increase tissue NAD⁺ and poly(ADP-ribose) levels but do not affect diethylnitrosamine-induced altered hepatic foci in Fischer-344 rats. *J Nutr* 1995;125:1455-1461.
- Jacob R, Swenseid M. Niacin. In: Ziegler EE, Filer LJ, eds. *Present knowledge in nutrition*. 7th ed. Washington, DC: ILSI Press; 1996:185-190.
- Jacobs DR Jr, Hebert B, Schreiner PJ, et al. Reduced cholesterol is associated with recent minor illness: the CARDIA Study: Coronary Artery Risk Development in Young Adults. *Am J Epidemiol* 1997;146(7):558-564.
- Jacobson EL. Niacin deficiency and cancer in women. *J Am Coll Nutr* 1993;12(4):412-416.
- Jacobson EL, Jacobson MK. Tissue NAD as a biochemical measure of niacin status in humans. *Methods Enzymol* 1997;280:221-230.
- Jacobson EL, Shieh WM, Huang AC. Mapping the role of NAD metabolism in prevention and treatment of carcinogenesis. *Mol Cell Biochem* 1999;193(1-2):69-74.
- Jacobson MK, Jacobson EL. Discovering new ADP-ribose polymer cycles: protecting the genome and more. *Trends Biochem Sci* 1999;24(11):415-417.
- Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. *Am J Cardiol* 1994;73:25D-29D.
- Jacques PF, Chylack LT Jr, Hankinson SE, et al. Long-term nutrient intake and early age related nuclear lens opacities. *Arch Ophthalmol* 2001;119(7):1009-1019.
- Jenkins DJ, Kendall CW, Marchie A, et al. The effect of combining plant sterols, soy protein, viscous fibers, and almonds in treating hypercholesterolemia. *Metabolism* 2003;52(11):1478-1483.
- Johnsen SH, Mathiesen EB, Fosse E, et al. Elevated high-density lipoprotein cholesterol levels are protective against plaque progression: a follow-up study of 1952 persons with carotid atherosclerosis: The Tromso Study. *Circulation* 2005;112:498-504.
- Jonas WB, Rapoza CP, Blair WF. The effect of niacinamide on osteoarthritis: a pilot study. *Inflamm Res* 1996;45(7):330-334.
- Kahn SE, Beard JC, Schwartz MW, et al. Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. *Diabetes* 1989;38(5):562-568.
- Kallmann B, Burkhart V, Kroncke KD, et al. Toxicity of chemically generated nitric oxide towards pancreatic islet cells can be prevented by nicotinamide. *Life Sci* 1992;51:671-678.
- Kanter AS, Spencer D et al. Supplemental multivitamins or vitamin B complex significantly delay progression to AIDS and death in South African patients infected with HIV: abstract 217. Conference of Retroviruses and Opportunistic Infections. Chicago, 1998.
- Karthikeyan K, Thappa DM. Pellagra and skin. *Int J Dermatol* 2002;41(8):476-481. (Review)
- Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. *Circulation* 2006;114(25):2788-2797.
- Kashyap ML, Evans R, Simmons PD, et al. New combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well tolerated. *J Am Coll Cardiol* 2000;35(Suppl A):326.
- Kaufman W. *The common form of joint dysfunction: its incidence and treatment*. Brattleboro, VT: EL Hildreth and Company; 1949.
- Kaufman W. The use of vitamin therapy to reverse certain concomitants of aging. *J Am Geriatr Soc* 1955;3(11):927-936.
- Kaur S, Goraya JS, Thami GP, et al. Pellagrous dermatitis induced by phenytoin. *Pediatr Dermatol* 2002;19(1):93. (Case report)
- Keenan JM, Fontaine PL, Wenz JB, et al. Niacin revisited: a randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. *Arch Intern Med* 1991;151:1424-1432.
- Kellman M. Bursitis: a new chemotherapeutic approach. *J Am Osteopathic Assoc* 1962;61:896-903.
- Kiff RS, Quick CR. Does inositol nicotinate (Hexopal) influence intermittent claudication? A controlled trial. *Br J Clin Pract* 1988;42:141-145.
- Kime CE. Bell's palsy: a new syndrome associated with treatment by nicotinic acid: a guide to adequate medical therapy. *AMA Arch Otolaryngol* 1958;68(1):28-32.
- Knip M, Douek IF, Moore WP, et al. Safety of high dose nicotinamide: a review. *Diabetologia* 2000;43:1337-1345. (Review)
- Knopp RH. Drug treatment of lipid disorders. *N Engl J Med* 1999;341(7):498-511.
- Knopp RH. Evaluating niacin in its various forms. *Am J Cardiol* 2000;86(12A):51L-56L.
- Knopp RH. Niacin and hepatic failure. *Ann Intern Med* 1989;111:769. (Letter)
- Knopp RH, d'Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). *Diabetes Care* 2006;29(7):1478-1485.
- Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. *Metabolism* 1985;34(7):642-650.

Citations and Reference Literature: Vitamin B3

- Krauss RM, Siri PW. Metabolic abnormalities: triglyceride and low-density lipoprotein. *Endocrinol Metab Clin North Am* 2004;33(2): 405-415. (Review)
- Krauss RM, Yang H, Rieder MJ, et al. Haplotypes in the HMGCoA reductase gene influence plasma LDL level and LDL response to statin in African Americans and Caucasians: abstract 725. American Heart Association Scientific Sessions 2005. Dallas, Nov 14, 2005.
- Kunin RA. Manganese and niacin in the treatment of drug-induced tardive dyskinesias. *J Orthomol Psychiatry* 1976;5:4-27.
- Kuramitsu M, Okumura Y, Kuramitsu M, et al. [Alcoholic pellagra psychosis: six cases including an autopsied case.] *Seishin Shinkeigaku Zasshi* 1991;93(1):1-19. [Japanese]
- Kuroki F, Iida M, Tominaga M, et al. Multiple vitamin status in Crohn's disease. *Dig Dis Sci* 1993;38(9):1614-1618.
- Kuzniarz M, Mitchell P, Cumming RG, et al. Use of vitamin supplements and cataract: the Blue Mountains Eye Study. *Am J Ophthalmol* 2001;132(1):19-26.
- Lal SM, Hewett JE, Petroski G, et al. Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial. *Am J Kidney Dis* 1995;25:616-622.
- Lemaitre RN, Psaty BM, Heckbert SR, et al. Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study. *Arch Intern Med* 2002;162(12):1395-1400.
- Lampeter EF, Klinghammer A, Scherbaum WA, et al. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes: DENIS Group. *Diabetes* 1998;47:980-984.
- Lei TC, Virador VM, Vieira WD, et al. A melanocyte-keratinocyte coculture model to assess regulators of pigmentation in vitro. *Anal Biochem* 2002;305:260-268.
- Lewis CM, Canafax DM, Sprafka JM, et al. Double-blind randomized trial of nicotinamide on early-onset diabetes. *Diabetes Care* 1992;15:121-123.
- LeWitt PA. The neurotoxicity of the rat poison vacor: a clinical study of 12 cases. *N Engl J Med* 1980;302(2):73-77.
- Lehmann HE, Ban TA, Saxena BM. Nicotinic acid, thioridazine, fluoxymesterone and their combinations in hospitalized geriatric patients: a systematic clinical study. *Can Psychiatr Assoc J* 1972;17(4):315-320.
- Leonard JV, Marrs TC, Addison JM, et al. Intestinal absorption of amino acids and peptides in Hartnup disorder. *Pediatr Res* 1976;10(4): 246-249.
- Levy HB, Kohlhaas HK. Considerations for supplementing with coenzyme q10 during statin therapy. *Ann Pharmacother* 2006;40(2): 290-294.
- Loscalzo J. Homocysteine trials: clear outcomes for complex reasons. *N Engl J Med*. 2006;354(15):1629-1632. (Editorial)
- Lu JY, Yu CL, Wu MZ. Pellagra in an immunocompetent patient with cytomegalovirus colitis. *Am J Gastroenterol* 2001;96(3):932-934.
- Ludvigsson J, Samuelsson U, Johansson C, et al. Treatment with antioxidants at onset of type 1 diabetes in children: a randomized, double-blind placebo-controlled study. *Diabetes Metab Res Rev* 2001;17:131-136.
- Luria MH. Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio. *Arch Intern Med* 1988;148(11):2493-2495.
- Mahon BE, Levy HL. Maternal Hartnup disorder. *Am J Med Genet* 1986;24(3):513-518.
- Mahl M, Lange K. A long term study of the effect of nicotinic acid medication on hypercholesterolemia. *Am J Med Sci* 1963;65:673.
- Malik S, Kashyap ML. Niacin, lipids, and heart disease. *Curr Cardiol Rep* 2003;5:470-476.
- Majamaa K, Rusanen H, Remes AM, et al. Increase of blood NAD⁺ and attenuation of lactic acidemia during nicotinamide treatment of a patient with the MELAS syndrome. *Life Sci* 1996;58:691-699.
- Malik S, Kashyap ML. Niacin, lipids, and heart disease. *Curr Cardiol Rep* 2003;5:470-476.
- Mancinella G, Liuti G, Vartolo C, et al. [An infrequent complication of chronic alcoholic hepatopathy: pellagra.] *Clin Ter* 1980;92(6): 671-678. [Italian]
- Manku MS, Horrobin DF, Morse N, et al. Reduced levels of prostaglandin precursors in the blood of atopic patients: defective delta-6-desaturase function as a biochemical basis for atopy. *Prostaglandins Leukot Med* 1982;(6):615-628.
- Marcus R, Coulston AM. Water-soluble vitamins: the vitamin B complex and ascorbic acid. In: Hardman JG, Limbird LE, Molinoff PB, et al, eds. *The pharmacological basis of therapeutics*. 9th ed. New York: McGraw Hill; 1995:1555-1571.
- Marks JB, Skyler JS. Clinical review 17: immunotherapy of type 1 diabetes mellitus. *J Clin Endocrinol Metab* 1991;72:3-9.
- Maron BA, Loscalzo J. Homocysteine. *Clin Lab Med* 2006;26(3):591-609, vi.
- Martin PD, Dane AL, Schneck DW, et al. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. *Clin Ther* 2003;25:459-471.
- Marz R. *Medical nutrition from Marz*. 2nd ed. Portland, OR: Omni Press; 1997. (Review)

Citations and Reference Literature: Vitamin B3

- Mason M, Ford J, Wu HL. Effects of steroid and nonsteroid metabolites on enzyme conformation and pyridoxal phosphate binding. *Ann N Y Acad Sci* 1969;166(1):170-183.
- Matsui MS, Rozovski SJ. Drug-nutrient interaction. *Clin Ther* 1982;4(6):423-440.
- May HT, Muhlestein JB, Carlquist JF, et al. Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure. *Am J Cardiol* 2006;98(5):653-658.
- McCarty MF, Russell AL. Niacinamide therapy for osteoarthritis: does it inhibit nitric oxide synthase induction by interleukin 1 in chondrocytes? *Med Hypotheses* 1999;53(4):350-360.
- McCreanor GM, Bender DA. The metabolism of high intakes of tryptophan, nicotinamide, and nicotinic acid in the rat. *Br J Nutr* 1986;56:577-586.
- McGovern ME. Taking aim at HDL-C: raising levels to reduce cardiovascular risk. *Postgrad Med* 2005;117(4):29-39. (Review)
- McKenney JM, Proctor JD, Harris S, et al. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. *JAMA* 1994;271(9):672-677.
- Mears E, Vessey MP, Andolsek L, et al. Preliminary evaluation of four oral contraceptives containing only progestogens. *Br Med J* 1969;1(659):730-734.
- Meyer NA, Muller MJ, Herndon DN. Nutrient support of the healing wound. *N Horiz* 1994;2(2):202-214.
- Meyers CD, Carr MC, Park S, et al. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. *Ann Intern Med* 2003;139(12):996-1002.
- Meyers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. *Curr Opin Lipidol* 2004;15(6):659-665. (Review)
- Miesel R, Kurpisz M, Kroger H. Modulation of inflammatory arthritis by inhibition of poly(ADP ribose) polymerase. *Inflammation* 1995;19:379-387.
- Miettinen TA, Taskinen MR, Pelkonen R, et al. Glucose tolerance and plasma insulin in man during acute and chronic administration of nicotinic acid. *Acta Med Scand* 1969;186(4):247-253.
- Mohler H, Polc P, Cumin R, et al. Nicotinamide is a brain constituent with benzodiazepine-like actions. *Nature* 1979;278(5704):563-565.
- Molnar GD, Berge KG, Rosevear JW, et al. The effect of nicotinic acid in diabetes mellitus. *Metabolism* 1964;13(2):181-189.
- Moore MT. Treatment of multiple sclerosis with nicotinic acid and vitamin B1. *Arch Int Med* 1940;65:18.
- Morgan JM, Capuzzi DM, Guyton JR, et al. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. *J Cardiovasc Pharmacol Ther* 1996;1:195-202.
- Morrow JD, Parsons WG III, Roberts LJ II. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. *Prostaglandins* 1989;38:2:263-274.
- Murray M. Lipid-lowering drugs vs. inositol hexaniacinate. *Am J Nat Med* 1995;2:9-12.
- Murray M, Pizzorno J. *Encyclopedia of natural medicine*. Rocklin, CA: Prima Press; 1998, 354.
- Murray MF, Langan M, MacGregor RR. Increased plasma tryptophan in HIV-infected patients treated with pharmacologic doses of nicotinamide. *Nutrition* 2001;17(7-8):654-656.
- Negri E, Franceschi S, Bosetti C, et al. Selected micronutrients and oral and pharyngeal cancer. *Int J Cancer* 2000;86(1):122-127.
- Neumann R, Rappold E, Pohl-Markl H. Treatment of polymorphous light eruption with nicotinamide: a pilot study. *Br J Dermatol* 1986;115:77-80.
- Newbold HL, Mosher LR. Niacin and the schizophrenic patient. *Am J Psychiatry* 1970;127:535-536.
- Nicholls SJ, Tuzcu EM, Sipahi I, et al. Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). *Am J Cardiol* 2006;97(11):1553-1557.
- Nistico G, Preziosi P. Contraceptives, brain serotonin, and liver tryptophan pyrrolase. *Lancet* 1970;2(7665):213.
- Nomikos IN, Prowse SJ, Carotenuto P, et al. Combined treatment with nicotinamide and desferrioxamine prevents islet allograft destruction in NOD mice. *Diabetes* 1986;35(11):1302-1304.
- O'Hara J, Jolly PN, Nicol CG. The therapeutic efficacy of inositol nicotinate (Hexopal) in intermittent claudication: a controlled trial. *Br J Clin Pract* 1988;42(9):377-383.
- Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. *Ann Pharmacother* 2002;36:288-295.
- Osmond H, Hoffer A. Massive niacin treatment in schizophrenia: review of a nine-year study. *Lancet* 1962;1:316-319.
- Ovesen L. Vitamin therapy in the absence of obvious deficiency: what is the evidence? *Drugs* 1984;27(2):148-170.
- Park YK, Sempos CT, Barton CN, et al. Effectiveness of food fortification in the United States: the case of pellagra. *Am J Public Health* 2000;90(5):727-738.

Citations and Reference Literature: Vitamin B3

- Parkhomets PK, Kuchmerovskaia TM, Donchenko GV, et al. [Role of nicotinic acid and its derivatives in disorders of nervous system function.] *Ukr Biokhim Zh* 1995;67:3-11. [Russian]
- Pasmans SG, Preesman AH, van Vloten WA. [Pellagra (deficiency of vitamin B3 or of the amino acid tryptophan): a disease still extant in the Netherlands.] *Ned Tijdschr Geneesk* 1998;142(33):1880-1882. [Dutch]
- Pasternak RC, Brown LE, Stone PH, et al. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels: a randomized, placebo-controlled trial: Harvard Atherosclerosis Reversibility Project (HARP) study group. *Ann Intern Med* 1996;125(7):529-540.
- Patterson DJ, Dew EW, Gyorkey F, et al. Niacin hepatitis. *South Med J* 1983;76:240-241.
- Pauling L. On the orthomolecular environment of the mind: orthomolecular theory. *Am J Psychiatry* 1974;131:1251-1257.
- Pearlman BL. The new cholesterol guidelines. *Postgrad Med* 2002;112(2):13-26. (Review)
- Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL Study: a randomized controlled trial. *JAMA* 2005;294:2437-2445.
- Petley A, Macklin B, Renwick AG, et al. The pharmacokinetics of nicotinamide in humans and rodents. *Diabetes* 1995;44:152-155.
- Petrie WM, Ban TA. Vitamins in psychiatry: do they have a role? *Drugs* 1985;30:58-65.
- Petrie WM, Ban TA, Ananth JV. The use of nicotinic acid and pyridoxine in the treatment of schizophrenia. *Int Pharmacopsychiatry* 1981;16(4):245-250.
- Philipp CS, Cisar LA, Saidi P, et al. Effect of niacin supplementation on fibrinogen levels in patients with peripheral vascular disease. *Am J Cardiol* 1998;82(5):697-699, A9.
- Picciotto MR, Brunzell DH, Caldarone BJ. Effect of nicotine and nicotinic receptors on anxiety and depression. *Neuroreport* 2002;13(9):1097-1106. (Review)
- Picciotto MR, Caldarone BJ, Brunzell DH, et al. Neuronal nicotinic acetylcholine receptor subunit knockout mice: physiological and behavioral phenotypes and possible clinical implications. *Pharmacol Ther* 2001;92(2-3):89-108. (Review)
- Pitsavas S, Andreou C, Bascialla F, et al. Pellagra encephalopathy following B-complex vitamin treatment without niacin. *Int J Psychiatry Med* 2004;34(1):91-95. (Case report)
- Pollack H. Nicotinic acid and diabetes. *Diabetes* 1962;11(2):144.
- Polo V, Saibene A, Pontiroli AE. Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas. *Acta Diabetol* 1998;35:61-64.
- Pozzilli P, Browne PD, Kolb H. Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM: the Nicotinamide Trialists. *Diabetes Care* 1996;19(12):1357-1363.
- Pozzilli P, Visalli N, Signore A, et al. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). *Diabetologia* 1995;38:848-852.
- Prasad PV, Babu A, Paul EK, et al. Myxoedema pellagra: a report of two cases. *J Assoc Physicians India* 2003;51:421-422.
- Price JM, Brown RR, Yess N. Testing the functional capacity of the tryptophan-niacin pathway in man by analysis of urinary metabolites. *Adv Metab Disord* 1965;2:159-225.
- Price JM, Thornton MJ, Mueller LM. Tryptophan metabolism in women using steroid hormones for ovulation control. *Am J Clin Nutr* 1967;20(5):452-456.
- Procter A. Enhancement of recovery from psychiatric illness by methylfolate. *Br J Psychiatry* 1991;159:271-272.
- Pronsky Z. Powers and Moore's food-medications interactions. 9th ed. Pottstown, PA: Food-Medication Interactions; 1991. (Review)
- Rader JJ, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. *Am J Med* 1992;92:77-81. (Review)
- Radons J, Heller B, Burkle A, et al. Nitric oxide toxicity in islet cells involves poly(ADP-ribose) polymerase activation and concomitant NAD⁺ depletion. *Biochem Biophys Res Commun* 1994;199:1270-1277.
- Rasool AA, Hussain AA, Dittert LW. Solubility enhancement of some water-insoluble drugs in the presence of nicotinamide and related compounds. *J Pharm Sci* 1991;80(4):387-393.
- Robinson C, Weigly E. Basic nutrition and diet therapy. New York: MacMillan; 1984.
- Roe DA. Diet and drug interactions. New York: Van Nostrand Reinhold; 1989. (Review)
- Roe DA. Drug and nutrient interactions in the elderly diabetic. *Drug Nutr Interact* 1988;5(4):195-203. (Review)
- Roe DA. Drug-induced nutritional deficiencies. 2nd ed. Westport, CT: Avi Publishing; 1985.
- Roe DA. Risk factors in drug-induced nutritional deficiencies. In: Roe DA, Campbell T, eds. *Drugs and nutrients: the interactive effects*. New York: Marcel Dekker; 1984:505-523.

Citations and Reference Literature: Vitamin B3

- Rose DP, Adams PW. Oral contraceptives and tryptophan metabolism: effects of oestrogen in low dose combined with a progestagen and of a low-dose progestagen (megestrol acetate) given alone. *J Clin Pathol* 1972; 25(3):252-258.
- Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. *N Engl J Med* 1999;341(6):410-418.
- Sandler S, Andersson A. Long-term effects of exposure of pancreatic islets to nicotinamide in vitro on DNA synthesis, metabolism and B-cell function. *Diabetologia* 1986;29:199-202.
- Schatz DA, Bingley PJ. Update on major trials for the prevention of type 1 diabetes mellitus: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT). *J Pediatr Endocrinol Metab* 2001;14(Suppl 1):619-622.
- Schechtman G, Hiatt J. Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment. *Ann Intern Med* 1996;125(12):990-1000.
- Schmitz W. [Psychopathology of pellagra in children.] *Psychiatr Neurol Med Psychol (Leipz)* 1971;23(3):159-166. [German]
- Schoch HK. The US Veterans Administration cardiology drug-lipid study: an interim report. *Adv Exper Med Biol* 1968;4:405-420.
- Schwab RA, Bachhuber BH. Delirium and lactic acidosis caused by ethanol and niacin co-ingestion. *Am J Emerg Med* 1991;9:363-365.
- Schwartz GG, Olsson AG, Ezekowitz MD. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. *JAMA* 2001;285(13):1711-1718.
- Sifton DW, ed. Physicians desk reference. Montvale, NJ: Medical Economics Company, Inc; 2000:1346-1349, 2071-2073.
- Spence JD, Bang H, Chambless LE, et al. Vitamin Intervention For Stroke Prevention trial: an efficacy analysis. *Stroke* 2005;36(11):2404-2409.
- Sperduto RD, Hu TS, Milton RC, et al. The Linxian cataract studies: two nutrition intervention trials. *Arch Ophthalmol* 1993;111:1246-1253.
- Srikantia SG, Reddy MV, Krishnaswamy K. Electroencephalographic patterns in pellagra. *Electroencephalogr Clin Neurophysiol* 1968;25(4):386-388.
- Stadler R, Orfanos CE, Immel C. [Drug-induced pellagra.] *Hautarzt* 1982;33(5):276-280. (Case report) [German]
- Stockley IH. Drug Interactions. 6th ed. London: Pharmaceutical Press; 2002. (Review)
- Stratford MR, Dennis MF, Hoskin P, et al. Nicotinamide pharmacokinetics in humans: effect of gastric acid inhibition: comparison of rectal vs oral administration and the use of saliva for drug monitoring. *Br J Cancer* 1996;74:16-21.
- Stratigos JD, Katsambas AD. Pellagra: "a reappraisal." *Acta Vitaminol Enzymol* 1982;4(1-2):115-121. (Review)
- Stratigos JD, Katsambas A. Pellagra: a still existing disease. *Br J Dermatol* 1977;96(1):99-106.
- Stratigos J, Katsambas A, Galanopoulou P. Pellagra, serotonin and 5-HIAA. *Br J Dermatol* 1974;90(4):451-452.
- Studer M, Briel M, Leimenstoll B, et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. *Arch Intern Med* 2005;165:725-730. (Review)
- Suenaert P, Bulteel V, Den Hond E, et al. In vivo influence of nicotine on human basal and NSAID-induced gut barrier function. *Scand J Gastroenterol* 2003;38(4):399-408.
- Sunderland GT, Belch JJ, Sturrock RD, et al. A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease. *Clin Rheumatol* 1988;7:46-49.
- Tahmouh AJ, Alpers DH, Feigin RD, et al. Hartnup disease: clinical, pathological, and biochemical observations. *Arch Neurol* 1976;33(12):797-807.
- Taketomo CK, Hodding JH, Kraus DM. Pediatric dosage handbook. 5th ed. Hudson, OH: Lexicomp; 1998:783.
- Tall AR. Protease variants, LDL, and coronary heart disease. *N Engl J Med* 2006;354:1310-1312. (Editorial)
- Tang AM, Graham NHM, Kirby AJ, et al. Dietary micronutrient intake and risk of progression to acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus type 1 (HIV-1)-infected homosexual men. *Am J Epidemiol* 1993;138:937-951.
- Tang AM, Graham NM, Saah AJ. Effects of micronutrient intake on survival in human immunodeficiency virus type 1 infection. *Am J Epidemiol* 1996;143(12):1244-1256.
- Thomas RG, Wysor WG Jr. Alteration of serotonin metabolism in rats deficient in niacin and tryptophan. *Proc Soc Exp Biol Med* 1967;126(2):374-379.
- Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. *JAMA* 2003;289:1681-1690.
- Threlkeld DS, ed. Diuretics and cardiovasculars, antihyperlipidemic agents, HMG-CoA reductase inhibitors. In: Facts and Comparisons drug information. St Louis: Facts and Comparisons; 1998. (Review)
- Torkos S. Drug-nutrient interactions: a focus on cholesterol-lowering agents. *Int J Integrative Med*. 2000;2(3):9-13. (Review)

Citations and Reference Literature: Vitamin B3

- Tornvall P, Walldius G. A comparison between nicotinic acid and acipimox in hypertriglyceridaemia: effects on serum lipids, lipoproteins, glucose tolerance and tolerability. *J Intern Med* 1991;230(5):415-421.
- Trovato A, Nuhlicek DN, Midtling JE. Drug-nutrient interactions. *Am Fam Physician* 1991;44(5):1651-1658. (Review)
- Tsigvoulis G, Spengos K, Karandreas N, et al. Presymptomatic neuromuscular disorders disclosed following statin treatment. *Arch Intern Med* 2006;166:1519-1524.
- Tyson VC. Treatment of intermittent claudication. *Practitioner* 1979;223:121-126.
- USDA: Composition of foods: USDA handbook #8. Washington, DC: ARS, USDA; 1976-1986.
- Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. *Am J Cardiol* 2003;91:956-960.
- Velling DA, Dodick DW, Muir JJ. Sustained-release niacin for prevention of migraine headache. *Mayo Clin Proc* 2003;78(6):770-771.
- Visalli N, Cavallo MG, Signore A, et al. A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset type 1 diabetes (the IMDIAB VI). *Diabetes Metab Res Rev* 1999;15(3):181-185.
- Wald DS, Wald NJ, Morris JK, Law M. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. *BMJ* 2006;333(7578):1114-1117. (Editorial, Review)
- Waldo MC. Co-distribution of sensory gating and impaired niacin flush response in the parents of schizophrenics. *Schizophr Res* 1999;40:1:49-53.
- Wang D, Taylor, KD, Smith J, et al. IL1B and TRAF6 are associated with components of low-density lipoprotein cholesterol reduction during statin therapy: poster 3. American Heart Association Scientific Sessions 2005: Dallas, Nov 14, 2005.
- Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. *N Engl J Med* 2006;355(25):2631-2639.
- Warburg O, Christian W. Co-ferment problem. *Biochemie* 1934;274:122-125.
- Ward PE, Sutherland J, Glen EM, et al. Niacin skin flush in schizophrenia: a preliminary report. *Schizophr Res* 1998;29(3):269-274.
- Ware JH. The limitations of risk factors as diagnostic tools. *N Engl J Med* 2006;355(25):2615-2617. (Editorial)
- Wei L, Murphy MJ, MacDonald TM. Impact on cardiovascular events of increasing high density lipoprotein cholesterol with and without lipid lowering drugs. *Heart* 2006;92(6):746-751.
- Weitberg AB. Effect of nicotinic acid supplementation in vivo on oxygen radical-induced genetic damage in human lymphocytes. *Mutat Res* 1989;216(4):197-201.
- Welch GN, Upchurch GR Jr, Loscalzo J. Homocysteine, oxidative stress, and vascular disease. *Hosp Pract (Minneapolis)* 1997;32(6): 81-82, 85, 88-92. (Review)
- Welsh AL, Ede M. Inositol hexanicotinate for improved nicotinic acid therapy. *Int Record Med* 1961;174:9-15.
- Werbach MR. Foundations of nutritional medicine. Tarzana, CA: Third Line Press; 1997:210-211. (Review)
- Weterle R, Rybakowski J. [The niacin test in schizophrenia.] *Psychiatr Pol* 1990;24(2):116-120. [Polish]
- Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. *Ann Intern Med* 2005;142(2):95-104.
- Wilcken B, Yu JS, Brown DA. Natural history of Hartnup disease. *Arch Dis Child* 1977;52(1):38-40.
- Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. *Pharmacogenet Genomics* 2005;15(6):415-421.
- Winter SL, Boyer JL. Hepatic toxicity from large doses of vitamin B3 (nicotinamide). *N Engl J Med* 1973;289:1180-1182.
- Wittenborn JR, Weber ES, Brown M. Niacin in the long-term treatment of schizophrenia. *Arch Gen Psychiatry* 1973;28:308-315.
- Wolfe ML, Vartanian SF, Ross JL, et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. *Am J Cardiol* 2001;87(4):476-9, A7.
- Wood B, Rademaker M, Oakley A, et al. Pellagra in a woman using alternative remedies. *Australas J Dermatol* 1998;39(1):42-44. (Case report)
- Wyatt RJ. On the orthomolecular environment of the mind: orthomolecular theory: comment. *Am J Psychiatry* 1974;131:1258-1262.
- Wynn V. Vitamins and oral contraceptive use. *Lancet* 1975;1:561-564.
- Yee HS, Fong NT. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. *Ann Pharmacother* 1998;32(10):1030-1043.
- Yeshurun D, Slobodin G, Keren D, et al. Statin escape phenomenon: does it really exist? *Eur J Intern Med* 2005;16(3):192-194.
- Yin S, Sato I, Yamaguchi K. Comparison of selenium level and glutathione peroxidase activity in tissues of vitamin B-6 deficient rats fed sodium selenite or DL-selenomethionine. *J Nutr Biochem* 1992;3:633-643.

Citations and Reference Literature: Vitamin B3

- Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid (EPA) on major cardiovascular events in hypercholesterolemic patients: the Japan EPA Lipid Intervention Study (JELIS). American Heart Association Scientific Sessions 2005. Dallas, Nov 14, 2005.
- Yonemura Y, Takashima T, Miwa K, et al. Amelioration of diabetes mellitus in partially depancreatized rats by poly(ADP-ribose) synthetase inhibitors: evidence of islet B-cell regeneration. *Diabetes* 1984;33:401-404.
- Ziliotto GR, Lamberti G, Wagner A, et al. [Comparative studies of the response of normolipemic and dyslipemic aged subjects to 2 forms of delayed-action nicotinic acid polyesters: pentaerythrol tetranicotinate and inositol hexanicotinate: results of a controlled cross-over trial.] *Arch Sci Med (Torino)* 1977;134(4):359-394. [Italian]